The former Governor of Osun State and National Secretary of the African Democratic Congress, ADC, Ogbeni Rauf Aregbesola, has declared the party the only credible alternative political platform ahead ...

From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates dominated Europe’s leading cancer conference over the ...

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. published a new clinical trial of sacituzumab tirumotecan (sac-TMT), in combination with the ...

Former Anambra State Governor, Peter Obi’s 2027 presidential ambition is being shrouded in uncertainty as confusion continues to trail what platform he will contest the election. DAILY POST reports ...

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own data. The ...

A former Minister of Interior and National Secretary, African Democratic Congress, Rauf Aregbesola, and former Ekiti State Deputy Governor, Prof Kolapo Olusola-Eleka, on Tuesday condemned the attack ...

The African Democratic Congress has cautioned the National Assembly against its proposed plan to amend the Electoral Act and shift the 2027 general elections to November 2026, warning that such a move ...

Founder of the Citadel School of Government and Serving Overseer of the Citadel Global Community Church (CGCC), Pastor Tunde Bakare, has clarified that his recent remarks linking the African ...

USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally Round led by Venrock Healthcare Capital ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis as a treatment for a type of lung cancer. The US regulator cleared Emrelis ...

Takeda Pharmaceutical is bolstering its pipeline in a big way, committing $1.2 billion for rights to two late-stage Innovent Biologics cancer drugs and securing an exclusive option to license an early ...